Dhinesh Selvaraju: A Step Closer to the ‘Ideal Anticoagulant’?
Dhinesh Selvaraju, Clinical Research Assistant at Yuva Intern by Henry Harvin, shared a post on LinkedIn:
“A Step Closer to the ‘Ideal Anticoagulant’?
A significant advancement in thrombosis research is emerging from recent clinical evidence.
Bayer has reported encouraging Phase III results for its investigational oral Factor XIa inhibitor, Asundexian, evaluated in the OCEANIC-STROKE trial (2026) involving over 12,000 patients.
Key findings:
- Approximately 26% reduction in recurrent stroke risk
- No significant increase in major bleeding events
Why this matters ?
Despite their proven efficacy, current anticoagulants (DOACs, warfarin) are inherently limited by the risk of bleeding complications, often creating a therapeutic trade-off.
Asundexian introduces a novel mechanism:
- Selective inhibition of Factor XIa (intrinsic coagulation pathway)
- Targeting pathological thrombosis while preserving physiological hemostasis
Clinical significance:
- Reinforces the potential of Factor XI inhibition as a safer anticoagulation strategy
- Represents a promising shift in secondary stroke prevention
- Addresses a long-standing clinical challenge: Can thrombosis be prevented without increasing bleeding risk?
A paradigm shift in hemostasis:
This development reflects a broader transition in anticoagulant therapy:
From broad-spectrum anticoagulation to pathway-specific precision targeting
If validated through ongoing regulatory review, asundexian could redefine clinical practice in cerebrovascular risk management and set a new benchmark for next-generation anticoagulants.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials